Phase I Study to Determine the Maximum Tolerated Dose of HM781-36B Continuously Given in Patients With Advanced Solid Tumors and to Assess the Food Effect on Pharmacokinetic Profile
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2015
At a glance
- Drugs Poziotinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 12 Dec 2015 Pooled analysis of 2 trials including this study and another study [see CTP 700208666] were presented at the 38th Annual San Antonio Breast Cancer Symposium.
- 22 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Apr 2013 Planned End Date changed from 1 May 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.